Canary’s First-in-class Dual RNAi Gene Silencing Offers a Novel Approach to Weight Loss and Metabolic Disease Management
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing New York, November 18thth, 2024 – Canary Cure, a biotechnology company focused on developing innovative RNAi therapies, today announced the results of a diet-induced-obesity (DIO) mouse study demonstrating the potential of its first-in-class dual siRNA therapy, CCT-217, to […]
